Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 103.98 USD -1.04% Market Closed
Market Cap: 5.1B USD

EV/EBIT
Enterprise Value to EBIT

-18.4
Current
-15.4
Median
16
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-18.4
=
Enterprise Value
5B USD
/
EBIT
-272.6m USD
EBIT Growth EV/EBIT to Growth
US
Axsome Therapeutics Inc
NASDAQ:AXSM
Average EV/EBIT: 1 866.8
Negative Multiple: -18.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.7
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-37.4
2-Years Forward
EV/EBIT
35.3
3-Years Forward
EV/EBIT
9.3